<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980629</url>
  </required_header>
  <id_info>
    <org_study_id>M516102-EU03</org_study_id>
    <nct_id>NCT00980629</nct_id>
  </id_info>
  <brief_title>Dose-Finding Study of M516102 in the Treatment of Pruritus Associated With Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-blind, Parallel Group, Multi-centre Phase II Dose-Finding Study of M516102 in the Treatment of Pruritus Associated With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maruho Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maruho Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This study is to investigate the efficacy and safety of M516102 and to evaluate the dose
      response relationship of M516102 and placebo, in the treatment of pruritus associated with
      atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date>September 2010</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pruritus score</measure>
  </primary_outcome>
  <condition>Atopic Dermatitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M516102</intervention_name>
    <description>Twice a day</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Twice a day</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients (aged 18-65 years) with a diagnosis of AD.

          2. Female patients of child bearing potential must be using a medically acceptable form
             of contraception.

          3. Patients who are able and willing to give signed informed consent.

          4. Patients who have pruritus exceed the reference range.

        Exclusion Criteria:

          1. Patients who have a history of allergy to hydrocortisone.

          2. Patients who have a history of relevant drug hypersensitivity.

          3. Patients who have a history of contact dermatitis induced by a topical steroid.

          4. Patients who are taking, and who are unwilling not to take, any medications or therapy
             prohibited by the protocol for the complete duration of the study.

          5. Patients who have a history or presence of any cancer.

          6. Patients who have any renal or liver insufficiency, or clinically significant cardiac,
             renal or hepatic disease.

          7. Patients who, in the opinion of the investigator, are not deemed eligible as
             determined by medical history, physical examination or clinical laboratory safety
             tests.

          8. Patients who have pruritus associated with conditions other than AD.

          9. Patients who have pruritus only on the face and head.

         10. Patients who, in the opinion of the investigator, have clinically relevant history or
             presence of any disease, or surgical history other than AD which is likely to affect
             the conduct of the study.

         11. Patients who have used M5161(active ingredient of M516102).

         12. Patients who cannot communicate reliably with the investigator.

         13. Patients who are pregnant or lactating.

         14. Patients who have used any IMP and/or participated in any clinical trial within 3
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1</name>
      <address>
        <city>Warsaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH3 9YW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <last_update_submitted>November 2, 2010</last_update_submitted>
  <last_update_submitted_qc>November 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

